Current approaches and recent developments in the management of head and neck paragangliomas

Endocrine Reviews

Volumn 35, Issue 5, 2014, Pages 795-819

  Taïeb, David ^a   Kaliski, Alexandre ^b   Boedeker, Carsten C ^c,d   Martucci, Victoria ^e   Fojo, Tito ^f   Adler, John R ^g   Pacak, Karel ^e,f  

^a TIMONE HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c Department of Otorhinolaryngology/Head and Neck Surgery HELIOS Hanseklinikum Stralsund ^*  (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^g STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; CAROTID BODY TUMOR; CLINICAL FEATURE; DISEASE CARRIER; FAMILIAL CANCER; FOLLOW UP; GENE MUTATION; HEAD AND NECK PARAGANGLIOMA; HEAD AND NECK TUMOR; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CANCER; NONHUMAN; PARAGANGLIOMA; QUALITY OF LIFE; RADIOISOTOPE THERAPY; REVIEW; STEREOTACTIC RADIOSURGERY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR DIAGNOSIS; TUMOR LOCALIZATION; HEAD AND NECK NEOPLASMS;

HEAD AND NECK NEOPLASMS; HUMANS; PARAGANGLIOMA;

EID: 84908319337     PISSN: 0163769X     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2014-1026     Document Type: Review

References (182)

1. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and Genetics of Tumours of Endocrine Organs. Vol 8. 3rd ed. Lyon, France: World Health Organization; 2004.
2. Mannelli M, Castellano M, Schiavi F, et al. Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab. 2009; 94(5):1541-1547.
3. Sykes JM, OssoffRH. Paragangliomas of the head and neck. Otolaryngol Clin North Am. 1986;19(4):755-767.
4. le Douarin N, Kalcheim C. The Neural Crest. 2nd ed. Cambridge, UK: Cambridge University Press; 1999.
5. Unsicker K, Huber K, Schober A, Kalcheim C. Resolved and open issues in chromaffin cell development. Mech Dev. 2013;130(6-8):324-329.
6. Erickson D, Kudva YC, Ebersold MJ, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86(11): 5210-5216.
7. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL. EVA Investigators. J Clin Endocrinol Metab. 2013;98(1):E162-E173.
8. Lee JH, Barich F, Karnell LH, et al. National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer. 2002;94(3):730-737.
9. Jafri M, Whitworth J, Rattenberry E, et al. Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. Clin Endocrinol (Oxf). 2013;78(6):898-906.
10. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287(5454):848-851.
11. Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer. 2014;14(2):108-119.
12. Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002;39(3):178-183.
13. Piccini V, Rapizzi E, Bacca A, et al. Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. Endocr Relat Cancer. 2012;19(2): 149-155.
14. Neumann HP, Erlic Z, Boedeker CC, et al. Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res. 2009;69(8): 3650-3656.
15. Kunst HP, Rutten MH, de Mönnink JP, et al. SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res. 2011;17(2):247-254.
16. Baysal BE. Mitochondrial complex II and genomic imprinting in inheritance of paraganglioma tumors. Biochim Biophys Acta. 2013;1827(5):573-577.
17. Papathomas TG, Gaal J, Corssmit EP, et al. Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. Eur J Endocrinol. 2014;170(1):1-12.
18. Pasini B, McWhinney SR, Bei T, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet. 2008;16(1):79-88.
19. Carney JA. Carney triad. Front Horm Res. 2013;41:92-110.
20. Haller F, Moskalev EA, Faucz FR, et al. Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocr Relat Cancer. 2014;.
21. Rustin P, Munnich A, Rötig A. Succinate dehydrogenase and human diseases: new insights into a well-known enzyme. Eur J Hum Genet. 2002;10(5):289-291.
22. van Nederveen FH, Gaal J, Favier J, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009;10(8):764-771.
23. Yang C, Matro JC, Huntoon KM, et al. Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. FASEB J. 2012;26(11):4506-4516.
24. Lendvai N, Pawlosky R, Bullova P, et al. Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings. Endocrinology. 2014;155(1): 27-32.
25. Imperiale A, Elbayed K, Moussallieh FM, et al. Metabolomic profile of the adrenal gland: from physiology to pathological conditions. Endocr Relat Cancer. 2013;20(5): 705-716.
26. Rao JU, Engelke UF, Rodenburg RJ, et al. Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma. Clin Cancer Res. 2013;19(14):3787-3795.
27. Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005;8(2):143-153.
28. Dang L, White DW, Gross S, et al. Cancer-associatedIDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462(7274):739-744.
29. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399-408.
30. Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012;12(1):9-22.
31. Jokilehto T, Jaakkola PM. The role of HIF prolyl hydroxylases in tumour growth. J Cell Mol Med. 2010;14(4):758-770.
32. Qin N, de Cubas AA, Garcia-Martin R, et al. Opposing effects of HIF-1α and HIF-2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MAX. Int J Cancer. 2014;135(9):2054-2064.
33. Koh MY, Powis G. Passing the baton: the HIF switch. Trends Biochem Sci. 2012;37(9):364-372.
34. Burnichon N, Rohmer V, Amar L, et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab. 2009;94(8):2817-2827.
35. Burnichon N, Vescovo L, Amar L, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011; 20(20):3974-3985.
36. Dahia PL, Hao K, Rogus J, et al. Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res. 2005;65(21):9651-9658.
37. Eisenhofer G, Huynh TT, Pacak K, et al. Distinct gene expression profiles in norepinephrine- and epinephrineproducing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer. 2004; 11(4):897-911.
38. Favier J, Briere JJ, Burnichon N, et al. The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One. 2009;4(9):e7094.
39. Jochmanová I, Yang C, Zhuang Z, Pacak K. Hypoxiainducible factor signaling in pheochromocytoma: turning the rudder in the right direction. J Natl Cancer Inst. 2013; 105(17):1270-1283.
40. López-Jiménez E, Gómez-López G, Leandro-García LJ, et al. Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol. 2010;24(12):2382-2391.
41. Shankavaram U, Fliedner SM, Elkahloun AG, et al. Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas. Neoplasia. 2013;15(4):435-447.
42. Merlo A, de Quiros SB, Secades P, et al. Identification of a signaling axis HIF-1α/microRNA-210/ISCU independent of SDH mutation that defines a subgroup of head and neck paragangliomas. J Clin Endocrinol Metab. 2012;97(11): E2194-E2200.
43. Kaelin WG Jr, McKnight SL. Influence of metabolism on epigenetics and disease. Cell. 2013;153(1):56-69.
44. Letouzé E, Martinelli C, Loriot C, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell. 2013;23(6):739-752.
45. Pollard PJ, Brière JJ, Alam NA, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet. 2005;14(15):2231-2239.
46. Xiao M, Yang H, Xu W, et al. Inhibition of alpha-KGdependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations ofFHand SDH tumor suppressors. Genes Dev. 2012;26(12):1326-1338.
47. Eisenhofer G, Lenders JW, Siegert G, et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48(11):1739-1749.
48. van Duinen N, Steenvoorden D, Kema IP, et al. Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas. J Clin Endocrinol Metab. 2010;95(1):209-214.
49. van Duinen N, Corssmit EP, de Jong WH, Brookman D, Kema IP, Romijn JA. Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites. Eur J Endocrinol. 2013;169(3):377-382.
50. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6): 1915-1942.
51. Gimm O, DeMicco C, Perren A, Giammarile F, Walz MK, Brunaud L. Malignant pheochromocytomas and paragangliomas: a diagnostic challenge. Langenbecks Arch Surg. 2012;397(2):155-177.
52. Korpershoek E, Favier J, Gaal J, et al. SDHA Immunohistochemistry Detects Germline SDHA Gene Mutations in Apparently Sporadic Paragangliomas and Pheochromocytomas. J Clin Endocrinol Metab. 2011;96(9):E1472-E1476.
53. Peitzsch M, Prejbisz A, Kroiss M, et al. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma. Ann Clin Biochem. 2013;50(Pt 2):147-155.
54. de Wailly P, Oragano L, Radé F, et al. Malignant pheochromocytoma: new malignancy criteria. Langenbecks Arch Surg. 2012;397(2):239-246.
55. Pinato DJ, Ramachandran R, Toussi ST, et al. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. Br J Cancer. 2013;108(2):429-437.
56. Span PN, Rao JU, Oude Ophuis B, et al. Overexpression of the natural antisense hypoxia-inducible factor-1alpha transcript is associated with malignant phaeochromocytoma/paraganglioma. Endocr Relat Cancer. 2011;18(3): 323-331.
57. Murthy SR, Pacak K, Loh YP. Carboxypeptidase E: elevated expression correlated with tumor growth and metastasis in pheochromocytomas and other cancers. Cell Mol Neurobiol. 2010;30(8):1377-1381.
58. Eisenhofer G, Lenders JW, Goldstein DS, et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem. 2005;51(4):735-744.
59. Zelinka T, Musil Z, Dušková J, et al. Metastatic pheochromocytoma: does the size and age matter? Eur J Clin Invest. 2011;41(10):1121-1128.
60. Boedeker CC, Neumann HP, Maier W, Bausch B, Schipper J, Ridder GJ. Malignant head and neck paragangliomas in SDHB mutation carriers. Otolaryngol Head Neck Surg. 2007;137(1):126-129.
61. Ellis RJ, Patel D, Prodanov T, Nilubol N, Pacak K, Kebebew E. The presence of SDHB mutations should modify surgical indications for carotid body paragangliomas. Ann Surg. 2014;260(1):158-162.
62. van Hulsteijn LT, DekkersOM, Hes FJ, Smit JW, Corssmit EP. Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis. J Med Genet. 2012;49(12):768-776.
63. Zheng X, Wei S, Yu Y, et al. Genetic and clinical characteristics of head and neck paragangliomas in a Chinese population. Laryngoscope. 2012;122(8):1761-1766.
64. Loriot C, Burnichon N, Gadessaud N, et al. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. J Clin Endocrinol Metab. 2012;97(6): E954-E962.
65. Johnson MH. Head and neck vascular anatomy. Neuroimaging Clin North Am. 1998;8(1):119-141.
66. van den Berg R, Schepers A, de Bruïne FT, et al. The value ofMRangiography techniques in the detection of head and neck paragangliomas. European journal of radiology. 2004;52(3):240-245.
67. Neves F, Huwart L, Jourdan G, Reizine D, Herman P, Vicaut E, Guichard JP. Head and neck paragangliomas: value of contrast-enhanced 3D MR angiography. AJNR Am J Neuroradiol. 2008;29(5):883-889.
68. van den Berg R. Imaging and management of head and neck paragangliomas. Eur Radiol. 2005;15(7):1310-1318.
69. Arnold SM, Strecker R, Scheffler K, et al. Dynamic contrast enhancement of paragangliomas of the head and neck: evaluation with time-resolved 2D MR projection angiography. Eur Radiol. 2003;13(7):1608-1611.
70. Dong Y, Liu Q. Differentiation of malignant from benign pheochromocytomas with diffusion-weighted and dynamic contrast-enhanced magnetic resonance at 3.0 T. J Comput Assist Tomogr. 2012;36(4):361-366.
71. Bustillo A, Telischi F, Weed D, et al. Octreotide scintigraphy in the head and neck. Laryngoscope. 2004;114(3): 434-440.
72. Duet M, Sauvaget E, Pételle B, et al. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med. 2003; 44(11):1767-1774.
73. Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullaart RP. 111In-Octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med. 2008;49(8):1232-1237.
74. Muros MA, Llamas-Elvira JM, Rodríguez A, et al. 111Inpentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma. Nucl Med Commun. 1998;19(8):735-742.
75. Schmidt M, Fischer E, Dietlein M, et al. Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas. Eur J Nucl Med Mol Imaging. 2002;29(12):1571-1580.
76. Telischi FF, Bustillo A, Whiteman ML, et al. Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol Head Neck Surg. 2000;122(3):358-362.
77. Charrier N, Deveze A, Fakhry N, et al. Comparison of [111In]pentetreotide-SPECT and [18F]FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities. Clin Endocrinol (Oxf). 2011;74(1):21-29.
78. Gabriel S, Blanchet EM, Sebag F, et al. Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by 18F-FDOPA PET: focus on missed lesions. Clin Endocrinol (Oxf). 2013;79(2):170-177.
79. King KS, Chen CC, Alexopoulos DK, et al. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18Ffluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123Imetaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011; 96(9):2779-2785.
80. Miederer M, Fottner C, Rossmann H, et al. High incidence of extraadrenal paraganglioma in families with SDHx syndromes detected by functional imaging with [18F]fluorodihydroxyphenylalanine PET. Eur J Nucl Med Mol Imaging. 2013;40(6):889-896.
81. Timmers HJ, Chen CC, Carrasquillo JA, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18Ffluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94(12):4757-4767.
82. Kroiss A, Putzer D, Frech A, et al. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CTin patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging. 2013;40(12):1800-1808.
83. Maurice JB, Troke R, Win Z, Ramachandran R, Al-Nahhas A, Naji M, Dhillo W, Meeran K, Goldstone AP, Martin NM, Todd JF, Palazzo F, Tan T. A comparison of the performance of 68Ga-DOTATATE PET/CT and 123IMIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012;39(8):1266-1270.
84. Naji M, Al-Nahhas A. 68Ga-labelled peptides in the management of neuroectodermal tumours. Eur J NuclMedMol Imaging. 2012;39(Suppl 1):61-67.
85. Naji M, Zhao C, Welsh SJ, et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13(4):769-775.
86. Sharma P, Thakar A, SumanKCS, et al. 68Ga-DOTANOC PET/CT for Baseline Evaluation of Patients with Head and Neck Paraganglioma. J Nucl Med. 2013;54(6):841-847.
87. Blanchet EM, Gabriel S, Martucci V, et al. 18F-FDG PET/CT as a predictor of hereditary head and neck paragangliomas. Eur J Clin Invest. 2014;44(3):325-332.
88. Taïeb D, Varoquaux A, Chen CC, Pacak K. Current and future trends in the anatomical and functional imaging of head and neck paragangliomas. Semin Nucl Med. 2013; 43(6):462-473.
89. Timmers HJ, Eisenhofer G, Carrasquillo JA, et al. Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin Endocrinol (Oxf). 2009; 71(1):11-17.
90. Timmers HJ, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25(16):2262-2269.
91. Taïeb D, Sebag F, Barlier A, et al. 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med. 2009;50(5):711-717.
92. Taïeb D, Timmers HJ, Hindié E, et al. EANM2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012; 39(12):1977-1995.
93. Cosetti M, Linstrom C, Alexiades G, Tessema B, Parisier S. Glomus tumors in patients of advanced age: a conservative approach. Laryngoscope. 2008;118(2):270-274.
94. Fisch U, Mattox D. Microsurgery of the Skull Base. Stuttgart/New York: Georg Thieme Verlag; 1988:148-281.
95. Fisch U. Infratemporal fossa approach to tumours of the temporal bone and base of the skull. J Laryngol Otol. 1978;92(11):949-967.
96. Netterville JL, Jackson CG, Miller FR, Wanamaker JR, Glasscock ME. Vagal paraganglioma: a review of 46 patients treated during a 20-year period. Arch Otolaryngol Head Neck Surg. 1998;124(10):1133-1140.
97. Shamblin WR, ReMine WH, Sheps SG, Harrison EG Jr. Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. AmJ Surg. 1971;122(6):732-739.
98. Kieran MW, Kalluri R, Cho YJ. The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med. 2012;2(12): a006593.
99. Wild D, Bomanji JB, Benkert P, et al. Comparison of 68Ga- DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54(3):364-372.
100. Lieberson RE, Adler JR, Soltys SG, Choi C, Gibbs IC, Chang SD. Stereotactic radiosurgery as the primary treatment for new and recurrent paragangliomas: is open surgical resection still the treatment of choice? World Neurosurg. 2012;77(5-6):745-761.
101. Adjallé R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res. 2009; 41(9):687-696.
102. Moskovic DJ, Smolarz JR, Stanley D, et al. Malignant head and neck paragangliomas: is there an optimal treatment strategy? Head Neck Oncol. 2010;2:23.
103. Heesterman BL, Bayley JP, Tops CM, et al. High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations. Eur J Hum Genet. 2013;21(4):469-470.
104. Hensen EF, Jansen JC, Siemers MD, et al. The Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family. Eur J Hum Genet. 2010;18(1): 62-66.
105. Hes FJ, Weiss MM, Woortman SA, et al. Low penetrance of a SDHB mutation in a large Dutch paraganglioma family. BMC Med Genet. 2010;11:92.
106. Jansen JC, van den Berg R, Kuiper A, van der Mey AG, Zwinderman AH, Cornelisse CJ. Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer. 2000;88(12):2811-2816.
107. Langerman A, Athavale SM, Rangarajan SV, Sinard RJ, Netterville JL. Natural history of cervical paragangliomas: outcomes of observation of 43 patients. Arch Otolaryngol Head Neck Surg. 2012;138(4):341-345.
108. Platero-Luengo A, Gonzalez-Granero S, Duran R, et al. An O2-sensitive glomus cell-stem cell synapse induces carotid body growth in chronic hypoxia. Cell. 2014;156(1-2): 291-303.
109. Saldana MJ, Salem LE, Travezan R. High altitude hypoxia and chemodectomas. Hum Pathol. 1973;4(2):251-263.
110. Astrom K, Cohen JE, Willett-Brozick JE, Aston CE, Baysal BE. Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect. Hum Genet. 2003;113(3):228-237.
111. Persky MS, Setton A, Niimi Y, Hartman J, Frank D, Berenstein A. Combined endovascular and surgical treatment of head and neck paragangliomas-a team approach. Head Neck. 2002;24(5):423-431.
112. Foote RL, Pollock BE, Gorman DA, et al. Glomus jugulare tumor: tumor control and complications after stereotactic radiosurgery. Head Neck. 2002;24(4):332-338; discussion 338-339.
113. de Flines J, Jansen J, Elders R, et al. Normal life expectancy for paraganglioma patients: a 50-year-old cohort revisited. Skull Base. 2011;21(6):385-388.
114. van Hulsteijn LT, Louisse A, Havekes B, et al. Quality of life is decreased in patients with paragangliomas. Eur J Endocrinol. 2013;168(5):689-697.
115. Havekes B, van der Klaauw AA, Hoftijzer HC, et al. Reduced quality of life in patients with head-and-neck paragangliomas. Eur J Endocrinol. 2008;158(2):247-253.
116. Patetsios P, Gable DR, Garrett WV, et al. Management of carotid body paragangliomas and review of a 30-year experience. Ann Vasc Surg. 2002;16(3):331-338.
117. Papaspyrou K, Mewes T, Rossmann H, et al. Head and neck paragangliomas: Report of 175 patients (1989-2010). Head Neck. 2012;34(5):632-637.
118. Wang SJ, Wang MB, Barauskas TM, Calcaterra TC. Surgical management of carotid body tumors. Otolaryngol Head Neck Surg. 2000;123(3):202-206.
119. Anand VK, Alemar GO, Sanders TS. Management of the internal carotid artery during carotid body tumor surgery. Laryngoscope. 1995;105(3 Pt 1):231-235.
120. Robbins KT, Clayman G, Levine PA, et al. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch Otolaryngol Head Neck Surg. 2002;128(7):751-758.
121. Kollert M, Minovi A, Mangold R, Hendus J, Draf W, Bockmühl U. [Paraganglioma of the head and neck-tumor control, functional results and quality of life]. Laryngorhinootologie. 2006;85(9):649-656.
122. Hinerman RW, Mendenhall WM, Amdur RJ, Stringer SP, Antonelli PJ, Cassisi NJ. Definitive radiotherapy in the management of chemodectomas arising in the temporal bone, carotid body, and glomus vagale. Head Neck. 2001; 23(5):363-371.
123. Suárez C, Rodrigo JP, Bödeker CC, et al. Jugular and vagal paragangliomas: Systematic study of management with surgery and radiotherapy. Head Neck. 2013;35(8):1195-1204.
124. Forest JA 3rd, Jackson CG, McGrew BM. Long-term control of surgically treated glomus tympanicum tumors. Otol Neurotol. 2001;22(2):232-236.
125. Rapisarda A, Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol. 2012;9(7):378-390.
126. Schipper J, Spetzger U, Tatagiba M, et al. Juxtacondylar approach in temporal paraganglioma surgery: when and why? Skull Base. 2009;19(1):43-47.
127. Gstoettner W, Matula C, Hamzavi J, Kornfehl J, Czerny C. Long-term results of different treatment modalities in 37 patients with glomus jugulare tumors. Eur Arch Otorhinolaryngol. 1999;256(7):351-355.
128. Miller RB, Boon MS, Atkins JP, Lowry LD. Vagal paraganglioma: the Jefferson experience. Otolaryngol Head Neck Surg. 2000;122(4):482-487.
129. Paridaans MP, van der Bogt KE, Jansen JC, et al. Results from craniocaudal carotid body tumor resection: should it be the standard surgical approach? Eur J Vasc Endovasc Surg. 2013;46(6):624-629.
130. Tasar M, Yetiser S. Glomus tumors: therapeutic role of selective embolization. J Craniofac Surg. 2004;15(3):497-505.
131. Brenner DJ, Sachs RK, Peters LJ, Withers HR, Hall EJ. We forget at our peril the lessons built into the α/β model. Int J Radiat Oncol Biol Phys. 2012;82(4):1312-1314.
132. Brenner DJ. Exploring two two-edged swords. Radiat Res. 2012;178(1):7-16.
133. Lo SS, Fakiris AJ, Chang EL, et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010;7(1):44-54.
134. Sharp CD, Jawahar A, Warren AC, Elrod JW, Nanda A, Alexander JS. Gamma knife irradiation increases cerebral endothelial expression of intercellular adhesion molecule 1 and E-selectin. Neurosurgery. 2003;53(1):154-160; discussion 160-151.
135. Peña LA, Fuks Z, Kolesnick R. Stress-induced apoptosis and the sphingomyelin pathway. Biochem Pharmacol. 1997;53(5):615-621.
136. Ch'ang HJ, Maj JG, Paris F, et al. ATM regulates target switching to escalating doses of radiation in the intestines. Nat Med. 2005;11(5):484-490.
137. Fuks Z, Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell. 2005;8(2):89-91.
138. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 2001;293(5528):293-297.
139. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immunemediated abscopal effect when combined with anti- CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379-5388.
140. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005; 174(12):7516-7523.
141. Suárez C, Rodrigo JP, Mendenhall WM, et al. Carotid body paragangliomas: a systematic study on management with surgery and radiotherapy. Eur Arch Otorhinolaryngol. 2014;271(1):23-34.
142. Capatina C, Ntali G, Karavitaki N, Grossman AB. The management of head-and-neck paragangliomas. Endocr Relat Cancer. 2013;20(5):R291-R305.
143. Glasscock ME 3rd, Jackson CG, Johnson GD, Poe DS. Radiation therapy in chemodectoma treatment. Laryngoscope. 1988;98(4):465-466.
144. Spector GJ, Compagno J, Perez CA, Maisel RH, Ogura JH. Glomus jugulare tumors: effects of radiotherapy. Cancer. 1975;35(5):1316-1321.
145. Suit HD, Gallager HS. Intact Tumor Cells in Irradiated Tissue. Arch Pathol. 1964;78:648-651.
146. de Jong AL, Coker NJ, Jenkins HA, Goepfert H, Alford BR. Radiation therapy in the management of paragangliomas of the temporal bone. Am J Otol. 1995;16(3):283-289.
147. Al-Mefty O, Teixeira A. Complex tumors of the glomus jugulare: criteria, treatment, and outcome. J Neurosurg. 2002;97(6):1356-1366.
148. Hinerman RW, Amdur RJ, Morris CG, Kirwan J, Mendenhall WM. Definitive radiotherapy in the management of paragangliomas arising in the head and neck: a 35-year experience. Head Neck. 2008;30(11):1431-1438.
149. Lalwani AK, Jackler RK, Gutin PH. Lethal fibrosarcoma complicating radiation therapy for benign glomus jugulare tumor. Am J Otol. 1993;14(4):398-402.
150. Springate SC, Weichselbaum RR. Radiation or surgery for chemodectoma of the temporal bone: a review of local control and complications. Head Neck. 1990;12(4):303-307.
151. Holt A, Van Gestel D, ArendsMP, et al. Multi-institutional comparison of volumetric modulated arc therapy vs. intensity- modulated radiation therapy for head-and-neck cancer: a planning study. Radiat Oncol. 2013;8:26.
152. Lim CM, Clump DA, Heron DE, Ferris RL. Stereotactic body radiotherapy (SBRT) for primary and recurrent head and neck tumors. Oral Oncol. 2013;49(5):401-406.
153. Onal C, Yuksel O, Topkan E, Pehlivan B. Bilateral glomus tumor treated with PET-CT based conformal radiotherapy: a case report. Cases J. 2009;2:8402.
154. Wahl RL, Herman JM, Ford E. The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. Semin Radiat Oncol. 2011;21(2):88-100.
155. Liscák R, Simonová G, Vymazal J, Janousková L, Vladyka V. Gamma knife radiosurgery of meningiomas in the cavernous sinus region. Acta Neurochir (Wien). 1999;141(5): 473-480.
156. Bianchi LC, Marchetti M, Brait L, et al. Paragangliomas of head and neck: a treatment option with CyberKnife radiosurgery. Neurol Sci. 2009;30(6):479-485.
157. Gerszten PC, Ozhasoglu C, Burton SA, et al. CyberKnife frameless single-fraction stereotactic radiosurgery for benign tumors of the spine. Neurosurg Focus. 2003;14(5): e16.
158. Martiniova L, Perera SM, Brouwers FM, et al. Increased uptake of [123I]meta-iodobenzylguanidine, [1F]fluorodopamine, and [3H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocr Relat Cancer. 2011;18(1): 143-157.
159. Lim M, Bower R, Nangiana JS, Adler JR, Chang SD. Radiosurgery for glomus jugulare tumors. Technol Cancer Res Treat. 2007;6(5):419-423.
160. Wegner RE, Rodriguez KD, Heron DE, Hirsch BE, Ferris RL, Burton SA. Linac-based stereotactic body radiation therapy for treatment of glomus jugulare tumors. Radiother Oncol. 2010;97(3):395-398.
161. Henzel M, Hamm K, Gross MW, et al. Fractionated stereotactic radiotherapy of glomus jugulare tumors. Local control, toxicity, symptomatology, and quality of life. Strahlenther Onkol. 2007;183(10):557-562.
162. Poznanovic SA, Cass SP, Kavanagh BD. Short-term tumor control and acute toxicity after stereotactic radiosurgery for glomus jugulare tumors. Otolaryngol Head Neck Surg. 2006;134(3):437-442.
163. Muracciole X, Régis J. Radiosurgery and carcinogenesis risk. Prog Neurol Surg. 2008;21:207-213.
164. Guss ZD, Batra S, Limb CJ, et al. Radiosurgery of glomus jugulare tumors: a meta-analysis. Int J Radiat Oncol Biol Phys. 2011;81(4):e497-e502.
165. Hayashi M, Chernov MF, Lipski SM, et al. Do we really still need an open surgery for treatment of patients with vestibular schwannomas? Acta Neurochir Suppl. 2013; 116:25-36.
166. Sobol SM, Dailey JC. Familial multiple cervical paragangliomas: report of a kindred and review of the literature. Otolaryngol Head Neck Surg. 1990;102(4):382-390.
167. Velegrakis G, Kalikakis G, Karampekios S, Stefanaki K, Helidonis E. Bilateral paraganglioma of the vagus nerve [in German]. HNO. 2001;49(6):471-475.
168. Boedeker CC, Hensen EF, Neumann HP, et al. Genetics of hereditary head and neck paragangliomas. Head Neck. 2014;36(6):907-916.
169. Rattenberry E, Vialard L, Yeung A, et al. A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2013;98(7): E1248-E1256.
170. Hescot S, Leboulleux S, Amar L, et al. One-year progression- free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2013;98(10):4006-4012.
171. Cascón A, Tennant DA. From transcriptional profiling to tumor biology in pheochromocytoma and paraganglioma. Endocr Pathol. 2012;23(1):15-20.
172. Jimenez C, Rohren E, Habra MA, et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep. 2013;15(4):356-371.
173. Zovato S, Kumanova A, Demattè S, et al. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL). Horm Metab Res. 2012;44(5):411-414.
174. Argiris A, Mellott A, Spies S. PET scan assessment of chemotherapy response in metastatic paraganglioma. Am J Clin Oncol. 2003;26(6):563-566.
175. Nakazawa A, Higuchi T, Oriuchi N, Arisaka Y, Endo K. Clinical significance of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131Imetaiodobenzylguanidine therapy in malignant phaeochromocytoma. Eur J Nucl Med Mol Imaging. 2011; 38(10):1869-1875.
176. Truman JP, Garcia-Barros M, Kaag M, et al. Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PLoS One. 2010;5(8):e12310.
177. Lee JI, Itasaka S, Kim JT, Nam DH. Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. Oncol Rep. 2006;15(5):1163-1168.
178. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008; 358(19):2039-2049.
179. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186.
180. Jain RK. A new target for tumor therapy. N Engl J Med. 2009;360(25):2669-2671.
181. Richter S, Peitzsch M, Rapizzi E, et al. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. J Clin Endocrinol Metab. [July 11, 2014] doi.org/10.1210/jc.2014-2151.
182. Yamada Y, Bilsky MH, Lovelock DM, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys. 2008;71(2):484-490.